Structure-Property Relationships of Ba[Ti1−x(Ho0.5Nb0.5)x]O3(x = 0.05–0.90) Perovskite Ceramics

Tian, Cailan; Yue, Zhenxing

doi:10.1080/00150193.2013.849173

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aptamer AS1411 (also known as AGRO100), which can strongly bind to cell surface nucleolin uniquely expressed on tumour cells, has reach phase I and phase II clinical trials as the first nucleic acid aptamer drug for the treatment of cancer in humans [6,7]. Recently, our group has explored a series of siloxane-crosslinked gelatin nanoparticles (GS NPs) with controlled size and surface charges, demonstrating the transfection efficiency of GS NPs in vitro and in vivo [8,9]. However, the capacity for efficient drug delivery by combining the aptamer AS1411 and GS NPs has not yet been investigated.…”

Section: Introductionmentioning

confidence: 99%

AS1411 Aptamer Conjugated Gelatin-Siloxane Nanoparticles for targeted siRNA delivery

Zhao¹,

Tao²,

Zhang³

et al. 2017

Preprint

View full text Add to dashboard Cite

RNA interference (RNAi) has potential advantages over other gene therapy approaches due to its high specificity and the ability to inhibit target gene expression. Thus, developing a stable, safe, effective siRNA delivery system is necessary to achieve targeted therapy. Here, we developed such a system by conjugating gelatin-based nanoparticles with the nucleolin-targeted AS1411 aptamer and siRNA sequence together (Apt-GS/siRNA NPs) via a disulphide linker. These Apt-GS/siRNA NPs demonstrated favourable release of siRNA under reducing conditions owing to disulphide cleavage. Furthermore, the Apt-GS/siRNA NPs could selectively deliver siRNA to A549 cells overexpressing nucleolin via a nucleolin-mediated transmembrane process, subsequently resulting in efficient RNAi. These results indicated that the Apt-GS/siRNA NPs could facilitate nucleolin-targeted siRNA delivery and gene silencing in tumours.

show abstract

Section: Introductionmentioning

confidence: 99%